市場調査レポート

商品コード

1675414

肺がん治療市場：療法別、がんタイプ別、流通チャネル別、地域別、2025-2033年

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2025-2033

出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 430,566円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 574,136円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 717,706円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

肺がん治療市場の世界市場規模は、2024年に330億6,100万米ドルに達しました。今後、IMARC Groupは、2033年には726億1,070万米ドルに達し、2025～2033年の成長率（CAGR）は9.14％に達すると予測しています。同市場は、世界の喫煙や環境汚染による肺がん罹患率の急増、遺伝子プロファイルに基づく治療など個別化治療のさらなる開発、病態の早期発見のための診断技術の絶え間ない進歩などにより、着実な成長を遂げています。

肺がん治療市場分析：

主な市場促進要因：世界の肺がんの罹患率と死亡率の高さが、高い需要を生み出しています。

主要市場動向：腫瘍細胞内の特定の遺伝子変異に対処する治療法の増加により、市場は個別化医療の方向に発展します。また、AIや機械学習を診断プロセスに取り入れることで、そうした治療にアクセスするチャンスと精度が高まることも、主要な肺がん治療市場動向の1つとして作用しています。

地理的動向：市場分析によると、北米は強固なヘルスケア構造、医療費、先進的腫瘍学治療の早期利用により、肺がん治療に関する市場をリードしています。中国やインドを含むアジア太平洋地域は、医療意識の急速な高まりと医療提供体制の改善に基づいて市場を牽引しています。

競合情勢：肺がん治療市場の概要によると、市場は老舗の大手製薬企業と新興のバイオ企業の存在により競争が激しいです。また、大手企業は研究開発や提携を通じて製品ラインの革新と拡大を図っています。

課題と機会：中低所得国への肺がん治療の普及を阻む主な課題として、新がん治療薬の高価格が浮上し、アクセシビリティギャップを生み出しています。しかし、このような課題は、費用対効果の高いジェネリック医薬品やバイオシミラーを開発する最近の動向として増幅しています。

肺がん治療市場傾向：

世界の肺がん罹患率の上昇

肺がん治療市場の成長に寄与するもう一つの要因は、肺がんの罹患率の増加です。米国がん学会は、2024年までに米国で肺がんが発生すると推定しています。新たに発生するがんの数は、男性116,310人、女性118,270人を含む234,580人です。死亡者数は125,070人で、男性65,790人、女性59,280人です。これは、世界人口の急激な増加や、喫煙、大気汚染、環境汚染、職場での有害な出来事など、肺がんを引き起こす有害因子の蔓延によって裏付けられています。したがって、これは肺がん治療市場の統計にも影響を与えています。肺がんの罹患率は増加の一途をたどっており、より積極的な対策が必要です。それに伴い、肺がん治療のための薬剤を含む方法の開発・改良は常に発展しています。供給量の増加は、製薬会社にとって、試験や新規開発、品揃えの拡充を行う理由となります。それに伴い、より効果的な薬剤への需要も高まっています。したがって、肺がん治療は最も急速に成長しています。

個別化医療におけるイノベーション

肺がん治療市場の成長は、遺伝的特徴に基づいて患者一人ひとりを治療する個別化医療の開発によって大きく伸びています。最近の動向では、製薬業界はそのような変異を正確に攻撃する薬剤を開発・生産しています。これらは化学療法よりも効果が高く、副作用も少ないことが証明されています。肺がん治療市場予測は、個別化医療がこの腫瘍学の治療の基礎になることを示唆しています。さらに、精密医療が重視されるようになる背景には、診断の技術的進歩や、肺がんの進行に影響する遺伝的要因の理解の深まりがあります。その結果、製薬業界は個別化ソリューションへの投資を拡大し続け、医薬品開発を特定の患者のニーズに合致させ、肺がん治療市場を大きく前進させています。

診断と治療における絶え間ない進歩

技術革新は、特に診断と治療の提供において市場を牽引します。また、画像診断やAI支援診断ツールの改善により、肺がんを早期かつ正確に発見できるようになりました。これとともに、この概念は治療効果と患者の回復にとって画期的なものです。これとは別に、肺がん治療市場の最近の動向には、新しく開発された低侵襲手術技術の導入、強化された放射線治療アプローチ、ナノ粒子ベースの化学療法製剤を含む先進ドラッグデリバリーシステムなどが含まれます。加えて、先端技術の精度と有効性は、快適な治療と回復可能な患者の視界を想像することができないです。さらに、これらすべての技術の組み合わせが、前向きな市場見通しを生み出しています。

標的療法
- 主要セグメント
  - ベバシズマブ
  - ダブラフェニブ/トラメチニブ
  - エルロチニブ塩酸塩
  - オシメルチニブ
  - その他
免疫療法
- 主要セグメント
  - デュルバルマブ
  - ニボルマブ
  - アテゾリズマブ
  - ペムブロリズマブ
放射線療法
- 主要セグメント
  - 外部ビーム
  - 内部ビーム
  - 全身
化学療法

第7章市場内訳：がんタイプ別

非小細胞肺がん（NSCLC）
小細胞肺がん（SCLC）

第8章市場内訳：流通チャネル別

病院薬局
小売薬局
オンライン薬局
その他

第9章市場内訳：地域別

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場内訳：国別

第10章促進要因・抑制要因・機会

概要
促進要因
抑制要因
機会

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第13章価格分析

第14章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- GSK PLC
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Takeda Pharmaceutical Company Limited

図表

List of Figures

Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019-2024
Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2024
Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2024
Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2024
Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2024
Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2024 & 2033
Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million USD), 2025-2033
Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
Table 7: Global: Lung Cancer Therapeutics Market: Key Players

Product Code: SR112025A8336

The global lung cancer therapeutics market size reached USD 33,061.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 72,610.7 Million by 2033, exhibiting a growth rate (CAGR) of 9.14% during 2025-2033. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

Lung Cancer Therapeutics Market Analysis:

Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.

Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.

Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.

Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.

Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

Lung Cancer Therapeutics Market Trends:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

Lung Cancer Therapeutics Market Segmentation:

Breakup by Therapy:

Targeted Therapy
Bevacizumab
Dabrafenib/Trametinib
Erlotinib Hydrochloride
Osimertinib
Others
Immunotherapy
Durvalumab
Nivolumab
Atezolizumab
Pembrolizumab
Radiation Therapy
External Beam
Internal Beam
Systemic
Chemotherapy

Targeted therapy accounts for the majority of the market share

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other

Hospital pharmacies represents the leading market segment

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company Limited
Eli Lilly and Company
GSK PLC
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report:

How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
What are the key regional markets?
Which countries represent the most attractive lung cancer therapeutics market?
What is the breakup of the market based on the therapy?
Which is the most attractive therapy in the lung cancer therapeutics market?
What is the breakup of the market based on the cancer type?
Which is the most attractive cancer type in the lung cancer therapeutics market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the lung cancer therapeutics market?
What is the competitive structure of the market?
Who are the key players/companies in the global lung cancer therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy

6.1 Targeted Therapy
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Bevacizumab
  - 6.1.2.2 Dabrafenib/Trametinib
  - 6.1.2.3 Erlotinib Hydrochloride
  - 6.1.2.4 Osimertinib
  - 6.1.2.4 Others
- 6.1.2 Market Forecast
6.2 Immunotherapy
- 6.2.1 Market Trends
- 6.2.2 Key Segments
  - 6.2.2.1 Durvalumab
  - 6.2.2.2 Nivolumab
  - 6.2.2.3 Atezolizumab
  - 6.2.2.4 Pembrolizumab
- 6.2.2 Market Forecast
6.3 Radiation Therapy
- 6.3.1 Market Trends
- 6.3.2 Key Segment
  - 6.3.2.1 External Beam
  - 6.3.2.2 Internal Beam
  - 6.3.2.3 Systemic
- 6.3.2 Market Forecast
6.4 Chemotherapy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

7.1 Non-small Cell Lung Cancer (NSCLC)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Small Cell Lung Cancer (SCLC)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Amgen Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 AstraZeneca Plc
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 Boehringer Ingelheim International GmbH
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Bristol-Myers Squibb Company
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 Daiichi Sankyo Company Limited
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Eli Lilly and Company
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
- 14.3.8 GSK PLC
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
- 14.3.9 Merck & Co. Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
- 14.3.10 Novartis AG
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
- 14.3.11 Pfizer Inc.
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
- 14.3.12 Roche Holding AG
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials
- 14.3.13 Takeda Pharmaceutical Company Limited
  - 14.3.13.1 Company Overview
  - 14.3.13.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

肺がん治療市場：療法別、がんタイプ別、流通チャネル別、地域別、2025-2033年

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2025-2033

肺がん治療市場分析：

肺がん治療市場傾向：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の肺がん治療市場

第6章 市場内訳：療法別

第7章 市場内訳：がんタイプ別

第8章 市場内訳：流通チャネル別

第9章 市場内訳：地域別

第10章 促進要因・抑制要因・機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格分析

第14章 競合情勢